Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon in Primary IgA Nephropathy at Risk of ESRD
CTR20200301Phase 3Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nefecon in IgA nephropathy (IgAN), sponsored by Calliditas Therapeutics AB. Started Mar 2020; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20200301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200301.